<p>小野制药公司（OTCMKTS:OPHLF - 获取免费报告）在周五上涨了 14.5%。该股票最高交易价格为$18.67，最后交易价格为$18.67。在午盘交易中，约有 300 股被交易，较平均每日交易量 433 股下降了 31%。该股票之前的收盘价为$16.30。</p>
<p>获取 <strong>小野制药</strong> 的提醒：</p>
<h2>小野制药股票表现</h2>
<p>该公司的 50 日简单移动平均线为$14.02，200 日简单移动平均线为$12.43。公司的流动比率为 3.02，速动比率为 2.56，债务与股本比率为 0.10。该股票的市值为$87.7 亿，市盈率为 20.98，贝塔值为 0.25。</p>
<p>小野制药（OTCMKTS:OPHLF - 获取免费报告）最后一次公布季度财报是在 2 月 2 日，星期一。公司报告该季度每股收益为$0.40，超出市场共识预期的$0.29，超出幅度为$0.11。该季度公司的收入为$8.927 亿，而分析师预期为$7.2758 亿。小野制药的股本回报率为 7.76%，净利润率为 12.29%。</p>
<h2>小野制药公司简介</h2>
<p>（获取免费报告）</p>
<p>小野制药株式会社成立于 1717 年，总部位于日本大阪，是一家以研究为基础的制药公司，专注于创新疗法的发现、开发和营销。小野制药起源于传统药房，现已发展成为一家全球生物制药实体，致力于在多个治疗领域提供新的治疗选择，包括肿瘤学、免疫学、心血管疾病和抗病毒疾病。该公司开展全面的研究项目，涵盖从早期药物发现到临床开发的各个阶段。</p>
<p>小野制药最知名的产品之一是免疫检查点抑制剂 nivolumab，与百时美施贵宝合作以 Opdivo 的商标进行营销。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过小野制药</li>
<li>你的银行账户不再安全</li>
<li>Nvidia CEO 发出大胆的特斯拉呼吁</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在小野制药吗？</h2>
<p>在考虑小野制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而小野制药并不在名单上。</p>
<p>虽然小野制药目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

小野制药(ADR)

4528

<p>小野制药 (ADR)（OTCMKTS:OPHLF）股价上涨 14.5%，达到 18.67 美元，交易量为 300 股。该公司报告每股收益为 0.40 美元，超出预期，收入为 8.927 亿美金。小野专注于创新疗法，特别是在肿瘤学和免疫学领域，市值为 87.7 亿美元。分析师目前对该股票的评级为持有，暗示可能有更好的投资选择</p>

<p>Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) was up 14.5% on Friday . The stock traded as high as $18.67 and last traded at $18.67. Approximately 300 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 433 shares. The stock had previously closed at $16.30.</p>
<div class="lb-trans"><p>小野制药公司（OTCMKTS:OPHLF - 获取免费报告）在周五上涨了 14.5%。该股票最高交易价格为$18.67，最后交易价格为$18.67。在午盘交易中，约有 300 股被交易，较平均每日交易量 433 股下降了 31%。该股票之前的收盘价为$16.30。</p>
</div><p>Get <strong>Ono Pharmaceutical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>小野制药</strong> 的提醒：</p>
</div><h2>Ono Pharmaceutical Stock Performance</h2>
<div class="lb-trans"><h2>小野制药股票表现</h2>
</div><p>The firm has a fifty day simple moving average of $14.02 and a 200 day simple moving average of $12.43. The company has a current ratio of 3.02, a quick ratio of 2.56 and a debt-to-equity ratio of 0.10. The stock has a market cap of $8.77 billion, a price-to-earnings ratio of 20.98 and a beta of 0.25.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为$14.02，200 日简单移动平均线为$12.43。公司的流动比率为 3.02，速动比率为 2.56，债务与股本比率为 0.10。该股票的市值为$87.7 亿，市盈率为 20.98，贝塔值为 0.25。</p>
</div><p>Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last announced its quarterly earnings data on Monday, February 2nd. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.11. The company had revenue of $892.70 million for the quarter, compared to analyst estimates of $727.58 million. Ono Pharmaceutical had a return on equity of 7.76% and a net margin of 12.29%.</p>
<div class="lb-trans"><p>小野制药（OTCMKTS:OPHLF - 获取免费报告）最后一次公布季度财报是在 2 月 2 日，星期一。公司报告该季度每股收益为$0.40，超出市场共识预期的$0.29，超出幅度为$0.11。该季度公司的收入为$8.927 亿，而分析师预期为$7.2758 亿。小野制药的股本回报率为 7.76%，净利润率为 12.29%。</p>
</div><h2>Ono Pharmaceutical Company Profile</h2>
<div class="lb-trans"><h2>小野制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.</p>
<div class="lb-trans"><p>小野制药株式会社成立于 1717 年，总部位于日本大阪，是一家以研究为基础的制药公司，专注于创新疗法的发现、开发和营销。小野制药起源于传统药房，现已发展成为一家全球生物制药实体，致力于在多个治疗领域提供新的治疗选择，包括肿瘤学、免疫学、心血管疾病和抗病毒疾病。该公司开展全面的研究项目，涵盖从早期药物发现到临床开发的各个阶段。</p>
</div><p>One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.</p>
<div class="lb-trans"><p>小野制药最知名的产品之一是免疫检查点抑制剂 nivolumab，与百时美施贵宝合作以 Opdivo 的商标进行营销。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Ono Pharmaceutical</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过小野制药</li>
<li>你的银行账户不再安全</li>
<li>Nvidia CEO 发出大胆的特斯拉呼吁</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ono Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在小野制药吗？</h2>
</div><p>Before you consider Ono Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑小野制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ono Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而小野制药并不在名单上。</p>
</div><p>While Ono Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然小野制药目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

小野制药 (ADR) (OTCMKTS:OPHLF) 股价上涨 14.5% - 是否值得购买？